The global blood plasma market was valued at USD 27,861.25 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.2% during the forecast period. This growth trajectory underscores the increasing demand for plasma-derived therapies, propelled by the rising prevalence of chronic diseases, technological advancements in plasma fractionation, and expanded applications of plasma-derived products in therapeutics and diagnostics.
Market Overview
Blood plasma, the liquid component of blood, contains essential proteins, hormones, and nutrients. It plays a pivotal role in treating various medical conditions such as immunodeficiency disorders, hemophilia, liver diseases, and neurological disorders. As healthcare systems across the globe evolve, the need for safe and effective biologics derived from plasma continues to rise.
The blood plasma market has witnessed dynamic transformations, driven by global awareness of rare and chronic diseases and a simultaneous increase in investments by biopharmaceutical companies. The development of novel plasma fractionation technologies and plasma collection systems has also enhanced the quality and yield of plasma-derived products, ensuring their growing relevance in modern medicine.
Key Market Growth Drivers
-
Rising Prevalence of Immunodeficiency and Hemophilia Disorders
One of the primary drivers of the blood plasma market is the increasing prevalence of immune system-related disorders and bleeding disorders such as hemophilia. Plasma-derived immunoglobulins are essential in the treatment of primary and secondary immunodeficiency conditions. Moreover, coagulation factors derived from plasma are life-saving for patients with hemophilia A and B.
-
Growing Demand for Albumin in Critical Care
Albumin, a major component of blood plasma, is extensively used in treating trauma, burns, and liver diseases. The surge in surgical procedures and the growing elderly population have led to increased demand for albumin, especially in emergency and critical care settings. Countries such as China and India have seen a rapid increase in albumin consumption, driving regional market growth.
-
Technological Advancements in Plasma Fractionation
The adoption of advanced plasma fractionation technologies has improved the efficiency and safety of plasma product manufacturing. Automation in fractionation, cold ethanol fractionation methods, and hybrid systems have revolutionized the production process. This ensures high-purity products with reduced pathogen transmission risks, boosting their acceptance in clinical settings.
-
Expansion of Plasma Collection Centers
There has been significant growth in the number of plasma collection centers globally. The U.S. leads the market in plasma collection, with a robust infrastructure and favorable reimbursement policies. The expansion of these centers has ensured a consistent and high-quality supply of plasma for therapeutic use, supporting the market’s growth momentum.
Market Challenges
Despite its growth potential, the blood plasma market faces several challenges that could hinder its expansion:
-
High Cost of Plasma-Derived Products
The production of plasma-derived therapies is expensive due to complex fractionation processes and strict regulatory requirements. These high costs limit accessibility, especially in low- and middle-income countries, where public healthcare funding is limited.
-
Risk of Disease Transmission
Although modern techniques have significantly reduced the risk of pathogen transmission, there is still concern about the safety of plasma-derived products. The emergence of novel pathogens poses a potential threat, requiring constant vigilance and innovation in screening and purification processes.
-
Stringent Regulatory Frameworks
Plasma collection and processing are governed by stringent regulations that vary from country to country. Navigating these complex frameworks can be a significant hurdle for manufacturers seeking to expand into new markets. The need for compliance with Good Manufacturing Practices (GMP) and continuous regulatory audits can lead to increased operational costs.
-
Ethical and Supply Chain Concerns
Ethical concerns surrounding plasma donation, particularly in developing countries, remain a topic of debate. Moreover, the COVID-19 pandemic exposed vulnerabilities in the plasma supply chain, leading to shortages and disruptions that highlighted the need for supply chain resilience.
???????????????????? ???????????????? ???????? ???????????????????????? ???????????? ???????????????? ????????????????????????:
https://www.polarismarketresearch.com/industry-analysis/global-blood-plasma-market
Regional Analysis
North America
North America holds the largest share of the global blood plasma market, with the United States at the forefront. The region boasts a strong network of plasma collection centers and a favorable reimbursement landscape. Increasing awareness about plasma-derived therapies and strong R&D activities further contribute to market dominance. The presence of major industry players also ensures a high level of innovation and product availability.
Europe
Europe is the second-largest market, led by countries like Germany, the U.K., and France. A robust healthcare infrastructure, combined with governmental support for rare disease treatment, has fueled demand. However, regulatory variations across EU member states can pose market entry challenges.
Asia-Pacific
The Asia-Pacific region is expected to register the highest growth during the forecast period. Countries such as China, Japan, and India are seeing increased demand due to growing healthcare awareness, rising disposable incomes, and the expansion of local manufacturing capacities. Governments are investing in improving blood donation awareness and infrastructure, which will boost plasma availability.
Latin America and the Middle East & Africa
While these regions currently hold a smaller share, they represent untapped potential for market growth. Rising investments in healthcare infrastructure and increasing patient access to treatments are expected to drive future expansion. Initiatives to improve voluntary blood donation and expand plasma collection capabilities are underway in various countries.
Key Companies
Several key players dominate the global blood plasma market, investing heavily in R&D, strategic partnerships, and global expansion:
-
Grifols, S.A.
A leading global healthcare company based in Spain, Grifols is known for its vertically integrated business model encompassing plasma collection, fractionation, and distribution. The company has a strong presence in North America and Europe and continues to invest in expanding its collection network. -
CSL Behring
Headquartered in Australia, CSL Behring is a major manufacturer of plasma-derived and recombinant therapies. The company is renowned for its extensive product portfolio that includes treatments for immunodeficiencies, bleeding disorders, and neurological diseases. -
Takeda Pharmaceutical Company Limited
Following its acquisition of Shire, Takeda has become a major player in the blood plasma market. Its plasma-derived products are used in treating rare and complex diseases, and the company has made significant strides in expanding its plasma collection capabilities. -
Octapharma AG
Based in Switzerland, Octapharma is a key manufacturer of human proteins derived from plasma. Its offerings span hematology, immunotherapy, and critical care, and the company continues to invest in clinical trials and product innovation. -
Kedrion S.p.A.
An Italy-based company, Kedrion specializes in collecting and fractionating plasma for therapeutic use. It maintains a significant presence in Europe and Latin America and has been working to expand into the U.S. market.
Conclusion
The global blood plasma market is poised for sustained growth over the next decade, driven by medical advancements, increasing disease burden, and innovations in plasma processing. However, overcoming cost barriers, regulatory challenges, and ethical concerns will be essential to achieving inclusive growth.
Stakeholders across the value chain—including manufacturers, healthcare providers, and regulatory agencies—must collaborate to ensure a resilient, ethical, and efficient plasma supply chain. With proper strategic initiatives and investments, the market will continue to play a vital role in advancing modern healthcare, providing life-saving treatments for millions of patients worldwide.
More Trending Latest Reports By Polaris Market Research:Nephrology and Urology Devices Market
Nephrology and Urology Devices Market
Anorectal Manometry Systems Market
Saving The Environment with Electronic Waste Management Market
Material Handling Equipment MarketMaterial Handling Equipment Market
Pig Protein Concentrate Market
Dicyclopentadiene Polyesters Resin Market
Renewable methanol market: A cost-effective alternative for green electricity